SANA · Insider Trading
Sana Biotechnology, Inc. Common Stock
Every open-market purchase and sale reported by SANA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-06 | Hans Edgar Bishop | Director | A | +8,680 | — |
| 2026-08-27 | Dhavalkumar Dhirajlal Patel | EVP, Chief Scientific Officer | MIXED | +83,842 | −$169.16K |
| 2026-07-07 | Hans Edgar Bishop | Director | A | +6,297 | — |
| 2026-06-05 | Michelle Seitz | Director | A | +90,000 deriv. | — |
| 2026-06-05 | Robert Nelsen | Director | A | +90,000 deriv. | — |
| 2026-06-05 | Hans Edgar Bishop | Director | A | +90,000 deriv. | — |
| 2026-06-05 | Joshua H. Bilenker | Director | A | +90,000 deriv. | — |
| 2026-06-05 | Robert L. Rosiello | Director | A | +90,000 deriv. | — |
| 2026-06-05 | Patrick Y Yang | Director | A | +90,000 deriv. | — |
| 2026-06-05 | Richard Mulligan | Director | A | +90,000 deriv. | — |
| 2026-06-05 | Alise Reicin | Director | A | +90,000 deriv. | — |
| 2026-04-08 | Hans Edgar Bishop | Director | A | +7,763 | — |
| 2026-03-10 | Susan D. Wyrick | See Remarks | MIXED | +9,279 | −$13.70K |
| 2026-03-10 | Steve Harr | President & CEO | MIXED | +67,321 | −$75.82K |
| 2026-03-06 | Steve Harr | President & CEO | A | +1,100,000 deriv. | — |
| 2026-03-06 | Susan D. Wyrick | See Remarks | A | +252,083 deriv. | — |
| 2026-03-04 | Susan D. Wyrick | See Remarks | MIXED | +1,034 | −$1.92K |
| 2026-02-18 | Brian Piper | EVP, Chief Financial Officer | A | +1,100,000 deriv. | — |
| 2026-01-06 | Hans Edgar Bishop | Director | A | +6,157 | — |
| 2026-01-06 | Susan D. Wyrick | See Remarks | MIXED | +5,093 | −$10.28K |
| 2025-12-16 | Susan D. Wyrick | See Remarks | MIXED | +2,527 | −$4.56K |
| 2025-12-05 | Susan D. Wyrick | See Remarks | MIXED | +14,868 | −$17.34K |
| 2025-10-07 | Hans Edgar Bishop | Director | A | +5,628 | — |
| 2025-07-08 | Hans Edgar Bishop | Director | A | +7,842 | — |
| 2025-06-09 | Joshua H. Bilenker | Director | A | +80,000 deriv. | — |
| 2025-06-09 | Robert Nelsen | Director | A | +80,000 deriv. | — |
| 2025-06-09 | Mary Agnes Wilderotter | Director | A | +80,000 deriv. | — |
| 2025-06-09 | Michelle Seitz | Director | A | +80,000 deriv. | — |
| 2025-06-09 | Alise Reicin | Director | A | +80,000 deriv. | — |
| 2025-06-09 | Hans Edgar Bishop | Director | A | +80,000 deriv. | — |
| 2025-06-09 | Richard Mulligan | Director | A | +80,000 deriv. | — |
| 2025-06-09 | Robert L. Rosiello | Director | A | +115,000 deriv. | — |
| 2025-06-09 | Patrick Y Yang | Director | A | +80,000 deriv. | — |
| 2025-04-08 | Hans Edgar Bishop | Director | A | +16,339 | — |
| 2025-03-10 | Bernard J Cassidy | EVP & General Counsel | MIXED | +8,208 | −$7.25K |
| 2025-03-10 | Steve Harr | President & CEO | MIXED | +37,180 | −$32.82K |
| 2025-03-10 | Susan D. Wyrick | See Remarks | MIXED | +2,414 | −$2.14K |
| 2025-03-03 | Susan D. Wyrick | See Remarks | MIXED | +1,035 | −$1.25K |
| 2025-01-10 | FMR LLC | 10%+ Owner | Sell | −290,912 | −$1.89M |
| 2025-01-07 | Hans Edgar Bishop | Director | A | +14,285 | — |
| 2025-01-03 | Susan D. Wyrick | See Remarks | MIXED | +3,434 | −$2.58K |
| 2024-10-09 | Hans Edgar Bishop | Director | A | +5,938 | — |
| 2024-09-26 | Richard Mulligan | Director | Sell | −300,000 | −$1.20M |
| 2024-07-15 | Mary Agnes Wilderotter | Director | A | +65,000 deriv. | — |
| 2024-07-15 | Hans Edgar Bishop | Director | A | +65,000 deriv. | — |
| 2024-07-15 | Douglas G. Cole | Director | A | +65,000 deriv. | — |
| 2024-07-15 | Joshua H. Bilenker | Director | A | +65,000 deriv. | — |
| 2024-07-15 | Richard Mulligan | Director | A | +65,000 deriv. | — |
| 2024-07-15 | Robert Nelsen | Director | A | +65,000 deriv. | — |
| 2024-07-15 | Patrick Y Yang | Director | A | +65,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Robert Nelsen | Director | 12,447,375 | $29.31M |
| Steve Harr | President & CEO | 8,124,070 | $19.13M |
| Hans Edgar Bishop | Director | 5,863,480 | $13.81M |
| FMR LLC | 10%+ Owner | 4,707,423 | $11.09M |
| Richard Mulligan | Director | 2,848,121 | $6.71M |
| Dhavalkumar Dhirajlal Patel | EVP, Chief Scientific Officer | 224,510 | $528.72K |
| Susan D. Wyrick | See Remarks | 197,241 | $464.50K |
| Patrick Y Yang | Director | 149,250 | $351.48K |
| Bernard J Cassidy | EVP & General Counsel | 112,990 | $266.09K |
| Joshua H. Bilenker | Director | 20,000 | $47.10K |
| Mary Agnes Wilderotter | Director | 7,106 | $16.73K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SANA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.